Bilaal.Raja
Company record

LXRX  LEXICON PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Healthcare

Scale

Market cap
$810m
Revenue TTM
$42m
Net income TTM
$-61m
Free cash flow
—
Composite score
—
Sector rank
#2094

Valuation

P / E
—
EV / EBITDA
—
EV / sales
16.2
FCF yield
—
Yield vs 10-yr
-12.82pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-147.4%
EBITDA margin
-130.3%
ROE
-35.0%
ROIC
-154.2%
Revenue growth
24.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Exton was director of business development with Invida Pty Ltd and spent seven years with Eli Lilly Australia, where he held a variety of research, business development and sales positions.LEXICON PHARMACEUTICALS, INC., 10-K, period ended 2025-12-31, filed 2026-03-05

Read the full passage →